01.08.2005 16:12:00
|
King Pharmaceuticals Announces Date for Release of Second-Quarter 2005 Financial Results and Conference Call
BRISTOL, Tenn., Aug. 1 /PRNewswire-FirstCall/ -- King Pharmaceuticals, Inc. reported today that the Company plans to announce financial results for the second quarter ending June 30, 2005, prior to the market open on Tuesday, August 9, 2005. The Company also plans to provide a live conference call to discuss its financial results beginning at 1:00 p.m. E.D.T. later that same day. Conference call information will be provided when available via a subsequent press release.
King, headquartered in Bristol, Tennessee, is a vertically integrated pharmaceutical company that develops, manufactures, markets, and sells branded prescription pharmaceutical products. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.
This release contains forward-looking statements that reflect management's current views of future events and operations, including, but not limited to, statements pertaining to the anticipated date for release of the Company's financial results for the second quarter ending June 30, 2005 and subsequent conference call. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. An important factor that may cause results to differ is whether King is able to release the Company's financial results for second quarter ending June 30, 2005 and conduct its conference call as currently planned on August 9, 2005. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Pfizer Inc.mehr Nachrichten
Analysen zu Pfizer Inc.mehr Analysen
19.12.24 | Pfizer Neutral | UBS AG | |
17.12.24 | Pfizer Buy | Jefferies & Company Inc. | |
17.12.24 | Pfizer Neutral | UBS AG | |
17.12.24 | Pfizer Neutral | JP Morgan Chase & Co. | |
12.12.24 | Pfizer Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
Pfizer Inc. | 24,81 | -1,84% |
Indizes in diesem Artikel
S&P 500 | 6 116,29 | -0,04% |